After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback